Antipsychotic Drugs Market Size, Share, and Trends 2024 to 2033

Antipsychotic Drugs Market Size to Reach USD 31.37 Bn by 2033

The global antipsychotic drugs market size was valued at USD 17.43 billion in 2023 and is anticipated to reach around USD 31.37 billion by 2033, growing at a CAGR of 6.05% from 2024 to 2033.

Key Takeaways

• North America held the largest share of the market share of 53% in 2023.
• Europe is anticipated to gain a considerable market share in the upcoming years.
• By disease, the schizophrenia segment dominated the market in 2023.
• By disease, the bipolar disorder segment is observed to carry a significant share over the forecast period.
• By therapeutic class, the second-generation segment dominated the market in 2023.
• By therapeutic class, the third-generation segment is expected to grow at the fastest rate during the forecast period.
• By drug, the aripiprazole segment held a significant share of the market in 2023.
• By drug, the paliperidone palmitate segment is expected to grow at a significant rate during the forecast period.
• By distribution channel, the hospital pharmacies segment is expected to hold the largest market share during the forecast period.
• By distribution channel, the drug stores & retail pharmacies segment is expected to witness a notable rate of growth during the forecast period.

Antipsychotic Drugs Market Size in U.S. 2024 to 2033

The U.S. antipsychotic drugs market size was estimated at USD 6.47 billion in 2023 and is predicted to be worth around USD 11.64 billion by 2033 at a CAGR of 6.10% from 2024 to 2033.

North America led the market with the biggest market share of 53% in 2023, the region is observed to sustain the position throughout the forecast period. The strong prevalence of psychiatric illness in the region and the presence of top biopharmaceutical companies are several factors that drive market growth in the region during the estimated period. Furthermore, other factors, including the strong adoption of antipsychotics with technological authority in the region and general awareness of critical mental illness in the region, are anticipated to fuel the market growth.

• According to a report published by the National Center for Biotechnology Information in March 2023, 57.8 million adults in the United States had mental illness in 2021.
• As per the report published by the Alzheimer Society of Canada in September 2022, an estimated 1.7 million Canadians are expected to live with dementia by 2050.

Europe is anticipated to gain a considerable share of the antipsychotic drugs market over the forecast period. The great incidence of mental disorders in the area and rising awareness of psychiatric problems are to account for this. The rising focus on the development of advanced therapeutics for mental disorders in the region is observed to act as a growth factor for the market’s expansion. Moreover, the market is observed to grow.

• According to an article published by Informa UK Limited in April 2022, aging populations in developed nations are leading to more older adults with psychiatric disorders.

Antipsychotic Drugs Market Overview

Antipsychotics are medications used to treat severe mental illnesses like psychosis, as well as other emotional and mental disorders. They can also help relieve persistent hiccups and pain caused by restlessness in palliative care. Psychosis makes a person lose touch with reality, often leading to hallucinations or delusions. Hallucinations involve hearing voices that aren't real, while delusions are beliefs not based on reality. These medications help manage symptoms of psychosis and other mental health issues like bipolar disorder and mood disorders, which could potentially lead to psychosis. They work by adjusting neurotransmitter levels in the brain, which are chemicals that transmit messages throughout the brain. Antipsychotics mainly affect dopamine, a key neurotransmitter. An overactive dopamine system is thought to contribute to the hallucinations and delusions experienced during psychosis.

Growth Factors

• A rise in efforts by key players to expand the therapeutic applications of neurological drugs is anticipated to create opportunities in the antipsychotic drugs market.
• The growing incidence of schizophrenia and bipolar disorder is likely to create demand for these medications.
• The increasing geriatric population and prevalence of mental diseases further boost the growth of the antipsychotic drugs market.
• The demand for antipsychotic drugs is also growing because of the rise in information about mental illnesses.
• The increased prevalence of psychosis globally is one of the key factors driving the antipsychotic drugs market.

Antipsychotic Drugs Market Scope

Antipsychotic Drugs Market Dynamics

Driver

Rise in mental diseases worldwide

Healthcare systems and service providers are currently under stress due to the rise in mental diseases globally. The government is now focusing on creating a high and reliable level of information about diseases and their associated systems. Furthermore, the market players are investing and giving their best resources to innovate highly efficient and secure drugs that can be applied to treat people with mental disorders in all countries. Physicians are using telemedicine to deliver effective OTC treatments and provide guidelines on dispensing medications. This factor can also drive the growth of the antipsychotic drugs market.

• An August 2023 article published by the open access government signifies the use of telemedicine. Telemedicine overcomes the physical limitations of conventional services by utilizing a variety of applications such as telephone, video-conferencing platforms, and wearable devices.

Restraint

Lack of awareness about medications

The major factor expected to hinder the growth of the antipsychotic drugs market during the forecast period is a lack of knowledge and awareness about these medications. Most people are unaware of the fact that the incidence of psychotic disorders is increasing day by day worldwide. Moreover, even the patients who are suffering from this disease are unaware of the treatment and therapies that can benefit them in the future. This also prevents market players from expanding their business on a large scale.

Opportunities

Technological advancements and government funding

The antipsychotic drugs market is growing due to advancements in medical technology and increased competition. Government funding is expected to increase, and businesses will invest more in research and development (R&D), creating new opportunities for income and market expansion. The government is making efforts to educate the public about diseases and the effectiveness of medicines used to treat them.

Additionally, there is a growing demand for effective and safe medicines to treat patients with psychotic disorders worldwide. Companies are also focusing on developing injectable antipsychotic medications to address the need for easier monitoring of patients' drug intake.

• In May 2023, The FDA approved risperidone (Uzedy, Teva, and MedinCell), an extended-release injectable suspension and long-acting subcutaneous atypical antipsychotic injection for the treatment of schizophrenia in adults. According to a press release, the injection uses technology to control the steady release of risperidone, and therapeutic blood concentrations are reached within 6 to 24 hours of a single dose. It also offers flexible 1- and 2-month dosing intervals.

Efforts made by the WHO

Increasing efforts by the WHO to treat dementia and a rise in awareness about mental disorders are driving demand for these drugs. Moreover, the rise in mental disorders such as bipolar and schizophrenia among most of the population and investments made by government and private organizations are major factors in boosting the antipsychotic drugs market’s growth.

• According to data published by the World Health Organization (WHO) in March 2023, approximately 55 million people in the globe have dementia, and 60% of them are from low and middle-income countries in 2022.

Disease Insights

The schizophrenia segment dominated the antipsychotic drugs market in 2023 and is expected to grow at the fastest pace. This leading position is attributed to the strong prevalence of these diseases worldwide. Combined with many product launches, the rising geriatric population who are more prone to the onset of schizophrenia is also raising the demand for the medications used in this disease.

• According to the World Health Organization, in 2022, schizophrenia affected 24 million people worldwide.
• According to a report published by the United Nations in 2022, the share percentage of older adults worldwide is projected to increase from 10% in 2022 to 16% by 2050. The geriatric population is more susceptible to neurological disorders and continues to experience worse situations later in life.

Besides the schizophrenia segment, the bipolar disorder segment is observed to hold a significant share of the antipsychotic drugs market. Bipolar syndrome is considered the 6th largest contributor among the total disabled patients in the world by WHO; this can further drive the segment growth in the future.

Therapeutic Class Insights

The second-generation segment held the largest share of the antipsychotic drugs market over the forecast period. The segment's growth is linked to the presence of a huge number of second-generation drugs in the market, like HAFYERA, INVEGA, SEROQUEL, XR, ZYPREXA, etc., which are prominent second-generation drugs in the market. Moreover, the improved efficiency and safety of the drugs from this generation will drive the growth of the market.

The third-generation segment is expected to grow at the fastest rate during the forecast period in the antipsychotic drugs market. New technological advancements compared to other classes of medicine are some factors that contribute to the overall growth of the antipsychotic drugs market. The upcoming innovation in the drug development procedures is also observed to create a significant driver for the segment’s growth.

Drug Insights

The aripiprazole segment dominated the antipsychotic drugs market in 2023. The adoption of third-generation products increases this segment's sales. Also, product approvals are expected to register the highest growth in the forecast period.

• In April 2023, Otsuka America Pharmaceutical, Inc. (Otsuka) and Lundbeck announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for ABILIFY ASIMTUFII® (aripiprazole) extended-release injectable suspension for intramuscular use, a once-every-two-months injection for the treatment of schizophrenia in adults or for maintenance monotherapy treatment of bipolar I disorder in adults.

The paliperidone palmitate segment is expected to hold a considerable share of the antipsychotic drugs market during the projected period. This medication is used to treat certain mental and mood disorders. It functions by helping to restore the balance of chemical substances in the brain.

• In October 2022, Lupin launched Paliperidone Extended-Release Tablets to treat schizophrenia in the United States.

Distribution Channel Insights

The hospital pharmacies segment held the largest share of the antipsychotic drugs market in 2023. The segment is observed to sustain the position throughout the forecast period. This is because most treatment medications require prescriptions from qualified medical professionals after thorough examinations conducted at these institutions. Hospital pharmacies usually offer precise therapeutics with prescriptions. Thereby, the rate of purchasing antipsychotic drugs from hospital pharmacies is comparatively high.

The drug stores & retail pharmacies segment is expected to gain a significant share of the antipsychotic drugs market. These places are important for obtaining prescription refills, particularly for oral medications. Multiple pharmacy stores have started offering product knowledge at stores or via sites, this makes it even more convenient for buying drugs for patients.

Recent Developments

• In January 2023, Luye Pharma Group received the Food and Drug Administration approval for Rykindo to treat schizophrenia and bipolar disorders.
• In February 2022, Alkermes plc released positive results from ENLIGHTEN-early, a phase 3b study that evaluates the study of LYBALVI in schizophrenia disease.
• In January 2022, Otsuka Pharmaceutical Co., Ltd., its subsidiary Otsuka American Pharmaceutical, Inc., and Lundbeck, Inc. received the Food and Drug Administration approval for the supplemental new drug application of REXULTI for Schizophrenia in 13 to 17-year-old patients.
• In February 2022, Alkermes plc released encouraging results from ENLIGHTEN-early, a phase 3b research that evaluated the effectiveness of LYBALVI in the treatment of schizophrenia disorder.

Antipsychotic Drugs Market Companies

• Eli Lily and Company
• AstraZeneca plc
• GlaxoSmithKline plc
• Johnson & Johnson
• Otsuka Pharmaceutical Co, Ltd.
• Pfizer Inc.
• AbbVie Inc.
• Bristol-Myers Squibb
• Teva Pharmaceuticals
• Dr. Reddy's Laboratories

Segments Covered in the Report

By Therapeutic Class

• First Generation
• Second Generation
• Third Generation

By Disease

• Schizophrenia
• Bipolar Disorder
• Unipolar Depression
• Dementia
• Other Diseases

By Drug

• Risperidone
• Quetiapine
• Olanzapine
• Aripiprazole
• Others

By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa